Publications
Detailed Information
Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Dy, Grace K. | - |
dc.contributor.author | Govindan, Ramaswamy | - |
dc.contributor.author | Velcheti, Vamsidhar | - |
dc.contributor.author | Falchook, Gerald S. | - |
dc.contributor.author | Italiano, Antoine | - |
dc.contributor.author | Wolf, Juergen | - |
dc.contributor.author | Sacher, Adrian G. | - |
dc.contributor.author | Takahashi, Toshiaki | - |
dc.contributor.author | Ramalingam, Suresh S. | - |
dc.contributor.author | Dooms, Christophe | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Addeo, Alfredo | - |
dc.contributor.author | Desai, Jayesh | - |
dc.contributor.author | Schuler, Martin | - |
dc.contributor.author | Tomasini, Pascale | - |
dc.contributor.author | Hong, David S. | - |
dc.contributor.author | Lito, Piro | - |
dc.contributor.author | Tran, Qui | - |
dc.contributor.author | Jones, Simon | - |
dc.contributor.author | Anderson, Abraham | - |
dc.contributor.author | Hindoyan, Antreas | - |
dc.contributor.author | Snyder, Wendy | - |
dc.contributor.author | Skoulidis, Ferdinandos | - |
dc.contributor.author | Li, Bob T. | - |
dc.date.accessioned | 2024-01-04T08:00:35Z | - |
dc.date.available | 2024-01-04T08:00:35Z | - |
dc.date.created | 2023-12-11 | - |
dc.date.created | 2023-12-11 | - |
dc.date.created | 2023-12-11 | - |
dc.date.created | 2023-12-11 | - |
dc.date.issued | 2024-01 | - |
dc.identifier.citation | Future Oncology, Vol.20 No.3, pp.113-120 | - |
dc.identifier.issn | 1479-6694 | - |
dc.identifier.uri | https://hdl.handle.net/10371/198780 | - |
dc.description.abstract | What is this summary about?This is a plain language summary of a study called CodeBreaK 100. The CodeBreaK 100 study included patients with non-small-cell lung cancer that had spread outside the lung (advanced). Lung cancer is one of the most common forms of cancer.CodeBreaK 100 specifically looked at patients with a particular change(mutation) in the KRAS gene resulting in the mutated protein called KRAS G12C. The KRAS G12C mutation can lead to development and growth of lung cancer.Patients received a treatment called sotorasib, which has accelerated approval or full approval in over 50 countries for patients with non-small-cell lung cancer with the KRAS G12C mutation.The CodeBreaK 100 study looked at whether sotorasib is a safe and effective treatment for advanced non-small-cell lung cancer. Sotorasib is designed to specifically target and lock the mutated KRAS protein in the inactive state to treat non-small-cell lung cancer.What were the results? In total, 174 adults were treated with sotorasib. Treatment-related side effects were seen in 70% of patients and were severe in 21% of patients. The most common side effects included diarrhea, increased liver enzymes, nausea and tiredness. 70 (41%) patients responded to sotorasib and 144 (84%) patients had tumors that either remained stable or shrunk in size. 29 (41%) patients who responded to sotorasib responded for over 12 months. After 2 years, 9 patients with a response remained on sotorasib; there were no notable increases in tumor size or development of new tumors over this time. There were 5patients who received sotorasib for more than 2 years and continued to respond. Long-term benefit was seen for some patients. Patients also benefitted from treatment when the tumor expressed different amounts of a protein called PD-L1.In total, 33% of patients were still alive after 2 years.What do the results mean? Results show the long-term benefit of sotorasib therapy for people with advanced KRAS G12C-mutated non-small-cell lung cancer. Clinical Trial Registration: NCT03600883 (CodeBreaK 100) (ClinicalTrials.gov)What do the results mean? Results show the long-term benefit of sotorasib therapy for people with advanced KRAS G12C-mutated non-small-cell lung cancer. | - |
dc.language | 영어 | - |
dc.publisher | Future Medicine Ltd. | - |
dc.title | Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary | - |
dc.type | Article | - |
dc.identifier.doi | 10.2217/fon-2023-0560 | - |
dc.citation.journaltitle | Future Oncology | - |
dc.identifier.wosid | 001109914800001 | - |
dc.identifier.scopusid | 2-s2.0-85185394410 | - |
dc.citation.endpage | 120 | - |
dc.citation.number | 3 | - |
dc.citation.startpage | 113 | - |
dc.citation.volume | 20 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordAuthor | Clinical trials | - |
dc.subject.keywordAuthor | Lung | - |
dc.subject.keywordAuthor | Metastasis | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.